1.

PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis

1.

PCN130 QUALITY OF LIFE, OUTCOMES, AND COSTS IN THE BELGIAN POPULATION RECEIVING 90Y-ZEVALIN FOR NON-HODGKIN LYMPHOMA: A STUDY FOR REIMBURSEMENT REVISION

1.

PIN2 SEVERE SEPSIS: CLINICAL TRIAL VERSUS DAILY PRACTICE.A COST ANALYSIS IN BELGIUM

1.

PCN23 ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA IN CANCER—A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM

1.

PIN55 COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAÏVE, PI-RESISTANT, HIV-INFECTED ADULTS IN THE UNITED KINGDOM, BELGIUM, ITALY AND SWE...

1.

PCA6: COST OF POSTMENOPAUSAL BREAST CANCER IN BELGIUM: AN INCIDENCE BASED APPROACH

1.

The impact of Local Skin Reactions (LSRS) on Resource Use and Quality of Life Associated with Different Field Therapies for Actinic Keratosis. Results from a Belgian Expert Survey

1.

Cost-effectiveness of DRV/r 600/100 mg BID in treatment-experienced, LPV/r-naïve, PI-resistant, HIV-infected adults in the UK, Belgium, Italy and Sweden

1.

PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM

1.

PSS8 Non-Interventional Study on the Burden of Illness in Diabetic Macular Edema (DME) in Belgium